Navigation Links
Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
Date:9/23/2009

NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced results of the Open Label Extension (OLE) trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The OLE trial, conducted in Taiwan, enrolled 29 of the 37 Taiwanese patients that had completed the randomized, multi-center, multi-national (United States and Taiwan) dose-ranging Phase 2 study. This OLE represents the first trial to examine the long-term safety and efficacy of Zerenex as a phosphate binder. The treatment period in all previous Zerenex Phase 2 clinical trials did not exceed 28 days.

The OLE trial provided for a daily dose, ranging from 2 to 6 g/day of Zerenex, for a period of up to one year following completion of the 28-day, dose-ranging Phase 2 study. The average duration of the patients' participation in the OLE trial was 306 +/- 85 days.

Data from the OLE trial indicate that the mean serum phosphorus level throughout the trial was 5.22 +/- 0.18 mg/dL, and the mean product of calcium times phosphate (CaxP) was 49.06 +/- 2.15 mg(2)/dL(2), both within the normal range as recommended by the KDOQI guidelines. In addition, during the OLE trial, the administration of IV iron as a supplement was withheld in 8 patients (27.6%) for periods ranging from 3 to 6 months and the administration of EPO was withheld in 8 patients (27.6%) for short periods because the hemoglobin, hematocrit, and iron parameters were within normal clinical ranges as assessed by the investigator. There were no signs of potential iron overload in the study patients, and there were no Zerenex-related serious adverse events as noted by either the pati
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
10. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 The nation,s newest Actos ... Las Vegas courtroom.  Attorneys representing two ... men suffered severe effects, including death, after using the diabetes ... what they as a company knew, that their drug Actos ... Robert Eglet .  "In order to hold Takeda responsible it ...
(Date:8/27/2015)... , Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), ... that three abstracts featuring the use of ActiPatch®, its ... 9 th Congress of the European Pain Federation ... September 2015. The Company will also be exhibiting ... Gianluca Bagnato , department clinical and experimental rheumatology ...
(Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2First Pennsylvania Patient Treated in Landmark Vascular Study 2
(Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
(Date:8/28/2015)... Indianapolis, IN (PRWEB) , ... August 28, 2015 ... ... employee benefits advisory organization, is pleased to welcome TJS Insurance Group as its ... to employees and clients guides them and keeps them focused on their goals. ...
(Date:8/28/2015)... ... ... External Counterpulsation, also known as ECP or EECP, is a proven treatment ... ECP) machines with a full clinic licence to help people prevent and reverse heart ... prevent and reverse heart disease through its evidence-based integrative approach to heart ...
(Date:8/28/2015)... ... August 28, 2015 , ... Yisrayl Hawkins, Pastor and ... and pleads for swift actions to be taken in order to ease the ... , Yisrayl says scientists have yet to understand fully the real cause of global ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life ... of the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and ... over the last three years, PREVENT ranks higher on the list than any other ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... may be beneficial in preventing severe long-term disability in multiple ... treatment for the chronic progressive phase of MS, when serious ... Children's Hospital Boston study appearing in the Journal of Neuroscience, ... type of vitamin B3 known as nicotinamide cut the risk ...
... help reduce Alzheimer's disease, says a study on mice, but ... findings apply to people.// ,Jun Wang and other researchers ... mice with genes that order the production of amyloid-beta protein, ... reported the online edition of science magazine WebMD. ...
... the basic purpose of a sunscreen lotion as well as ... well on the threshold of a discovery; Scientists have found ... the fair skin people from tanning as well as guard ... David E. Fisher, director of the Melanoma Program at the ...
... 80% of people suffering from severe chronic lung disease ... of it.// ,Chronic Bronchitis and Emphysema constitute the ... lung tissue by smoking can lead to the development ... ,Professor Robert West, director of tobacco studies at Cancer ...
... particularly those with high levels of low-density lipoprotein ... according to a study in the September 20 ... specific class of lipoprotein particles found in human ... according to background information in the article. Studies ...
... kidney cancer has been rising over the last two decades, ... Center shows// that this increase is driven largely by the ... the rising incidence has been paralleled by greater use of ... fewer people dying. ,“With increased early detection and treatment ...
Cached Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:80% of lung disease remains ‘undiagnosed’. 2Health News:High Levels of Lipoprotein(a) in Women is Associated With Cardiovascular Risk 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 3
The Onyx® 9500 worlds first self-contained digital fingertip pulse oximeter incorporates the electronics and the sensor into one unit....
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
... The Invacare Digital Pulse ... and pulse strength. It is ... measurements on challenging patients. The ... other artifacts, informs the operator ...
Rad-9™...
Medicine Products: